LinkedInFacebookTwitterRssEmail
1.877.909.5210|info@avancebio.com

News & Events

16 10, 2020

MASS General researchers show ddPCR brain tumor liquid biopsy assay has tenfold improvement in sensitivity over any prior assay

2020-10-16T15:29:16+00:00

Genetic mutations that promote the growth of the most common type of adult brain tumors can be accurately detected and monitored in blood samples using an enhanced form of liquid biopsy developed by researchers at Harvard-affiliated Massachusetts General Hospital (MGH). Comparing blood samples from patients with gliomas with tumor biopsy tissues from the same patients, [...]

MASS General researchers show ddPCR brain tumor liquid biopsy assay has tenfold improvement in sensitivity over any prior assay2020-10-16T15:29:16+00:00
12 08, 2020

FDA approves first liquid biopsy next-generation sequencing companion diagnostic test

2020-08-12T13:40:43+00:00

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to [...]

FDA approves first liquid biopsy next-generation sequencing companion diagnostic test2020-08-12T13:40:43+00:00
2 07, 2020

Join Us At Onco Cell Therapy Summit – July 7-8 – Online

2020-07-02T17:53:14+00:00

Avance Biosciences specializes in assay development, validation, and sample testing services supporting our clients for their drug development initiatives and GMP manufacturing activities.  We are a leader in applying state-of-art technologies, such as next generation sequencing (NGS) and digital droplet PCR (ddPCR), to improve the effectiveness and efficiency of biologic tests. [...]

Join Us At Onco Cell Therapy Summit – July 7-8 – Online2020-07-02T17:53:14+00:00
29 01, 2020

Join Us At BioProcess International US West – March 9-12 – Santa Clara, CA

2020-01-30T14:09:21+00:00

Avance Biosciences specializes in assay development, validation, and sample testing services supporting our clients for their drug development initiatives and GMP manufacturing activities.  We are a leader in applying state-of-art technologies, such as next generation sequencing (NGS) and digital droplet PCR (ddPCR), to improve the effectiveness and efficiency of biologic tests. [...]

Join Us At BioProcess International US West – March 9-12 – Santa Clara, CA2020-01-30T14:09:21+00:00
17 12, 2019

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace dying cells in retina

2019-12-18T12:38:05+00:00

NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment. Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), [...]

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace dying cells in retina2019-12-18T12:38:05+00:00
29 10, 2019

FDA grants CAR T-cell therapy RMAT designation for multiple myeloma

2019-10-29T15:36:52+00:00

The United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple myeloma (rrMM)...

FDA grants CAR T-cell therapy RMAT designation for multiple myeloma2019-10-29T15:36:52+00:00
22 10, 2019

New gene therapy drug brings in $160 million, beating expectations

2019-10-22T13:29:42+00:00

ZURICH (Reuters) - Swiss drugmaker Novartis (NOVN.S) boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world’s most expensive one-time treatment. CEO Vas Narasimhan’s bet on the potential cure for spinal muscular atrophy (SMA) has drawn scrutiny, initially due to its [...]

New gene therapy drug brings in $160 million, beating expectations2019-10-22T13:29:42+00:00
4 10, 2019

First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers

2019-10-22T12:53:12+00:00

From City of Hope by Letisia Marquez The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma cells in animal models, according to City of Hope research published today in Science Translational Medicine. The new therapy will be used in [...]

First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers2019-10-22T12:53:12+00:00
19 08, 2019

Join Us At CAR-TCR Summit – Sept 10-13 – Boston, MA

2019-08-22T11:53:50+00:00

Avance offers CAR T-Cell therapy testing services supporting drug development and manufacturing. Avance Biosciences provides the development, validation and testing services for assays required by regulatory agencies for thorough characterization of manufactured CAR T-cells, and routine monitoring of modified T-cells levels in patients’ blood during the clinical trial or patient treatment phase...

Join Us At CAR-TCR Summit – Sept 10-13 – Boston, MA2019-08-22T11:53:50+00:00
19 06, 2019

Phage Testing of Bacterial Cultures

2019-06-19T12:08:17+00:00

Regulatory agencies require companies using microbial cell lines that produce products for human use to regularly complete biosafety testing to ensure that cell banks are free of phage contamination. Bacteriophage (phage) is a virus that infects and replicates within bacteria1, basically bacterial predators. One hundred times smaller than a bacterium, phage are found wherever [...]

Phage Testing of Bacterial Cultures2019-06-19T12:08:17+00:00

CONTACT INFORMATION

About Us

Avance Biosciences is specialized in assay development, assay validation, and sample testing using Next Generation DNA Sequencing, Sanger Sequencing, Quantitative PCR, and other biological methods to support Drug Development and Manufacturing.

When you partner with Avance Biosciences, we give you undivided attention, share our experience and knowledge, and respond to your needs in a timely manner. Contact our technical staff to discuss how we can support you in your project!

CONTACT US

THE LATEST NEWS